Immatics  Developing immunotherapies against solid tumours

In July 2020, immatics completed its reverse merger with Arya Sciences Acquisition Corp, a special purpose acquisition company (SPAC), and commenced trading on Nasdaq.

Leveraging its proprietary XPRESIDENT® platform, immatics has identified numerous MHC-bound peptide antigens expressed on tumour cells (TUMAPs) and these TUMAPs now serve as targets for diverse anti-cancer approaches, including adoptive cellular therapy, soluble T-cell receptors-based therapy and monoclonal antibodies. While pursuing its own preclinical and clinical pipeline of cancer therapeutics, immatics has formed a joint venture with the world’s largest cancer research center (MD Anderson Cancer Center, Houston, Texas) for the development of cell-based therapies. In parallel, immatics has created significant strategic collaborations with Roche, Amgen, Genmab, Celgene, GSK and BMS.



Case facts





Involved Team